Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

Could K17 be a Key Treatment Target for Pancreatic Cancer?

A national team of cancer researchers led by Drs. Kenneth Shroyer and Natalia Marchenko at Stony Brook Medicine, and Dr. Luisa Escobar-Hoyos of Yale School of Medicine discovered that the protein K17 is a key driver for chemoresistance to gemcitabine, an agent that is often used to treat a wide range of cancers, including advanced tumors of the pancreas, lungs and breast.

May 20, 2026


May 21 2026

May 20 2026

May 19 2026

May 18 2026

May 17 2026

May 16 2026

May 15 2026

May 14 2026

May 13 2026

May 12 2026

May 11 2026

May 10 2026

May 8 2026

May 7 2026